Europe Docetaxel Market Size & Outlook, 2025-2030
Related Markets
Europe docetaxel market highlights
- The Europe docetaxel market generated a revenue of USD 404.1 million in 2024.
- The market is expected to grow at a CAGR of 5.7% from 2025 to 2030.
- In terms of segment, breast cancer was the largest revenue generating indication in 2024.
- Squamous Cell Carcinoma of the Head and Neck is the most lucrative indication segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 404.1 million |
| Market revenue in 2030 | USD 565.3 million |
| Growth rate | 5.7% (CAGR from 2025 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Squamous Cell Carcinoma of the Head and Neck |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck |
| Key market players worldwide | Phyton Biotech, Rochem, Alchem International, LGM Pharma, HRV Global LifeSciences, Teva Active Pharmaceutical Ingredients, Arch Pharmalabs, Aspen Pharmacare, Cipla Ltd DR |
Other key industry trends
- In terms of revenue, Europe region accounted for 32.1% of the global docetaxel market in 2024.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 474.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Docetaxel Market Scope
Docetaxel Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Active Pharmaceutical Ingredients | View profile | 5001-10000 | http://www.tapi.com/ | |
| HRV Global LifeSciences | View profile | 101-250 | Hyderabad, Andhra Pradesh, India, Asia | https://hrvglobal.com |
| Alchem International | View profile | 11-50 | Delhi, Delhi, India, Asia | https://www.alchemlife.com |
| Rochem | View profile | 11-50 | Hauppauge, New York, United States, North America | https://rochemintl.com/ |
| Phyton Biotech | View profile | 51-100 | Delta, British Columbia, Canada, North America | http://www.phytonbiotech.com |
| Arch Pharmalabs | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.archpharmalabs.com |
| Aspen Pharmacare | View profile | 10001+ | Durban, NA - South Africa, South Africa, Africa | https://www.aspenpharma.com |
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | https://lgmpharma.com/ |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
Europe docetaxel market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to docetaxel market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 35.04% in 2024. Horizon Databook has segmented the Europe docetaxel market based on breast cancer, non-small cell lung cancer (nsclc), hormone refractory prostate cancer, gastric adenocarcinoma, squamous cell carcinoma of the head and neck covering the revenue growth of each sub-segment from 2018 to 2030.
Europe exhibits steady docetaxel market growth, led by Germany, France, and the UK. The region benefits from advanced cancer care infrastructure, supportive reimbursement frameworks, and increased public health initiatives. National cancer strategies and pan-European clinical collaboration further drive the adoption of docetaxel. Hospital pharmacy dominance ensures streamlined access across oncology units.
Reasons to subscribe to Europe docetaxel market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe docetaxel market databook
-
Our clientele includes a mix of docetaxel market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe docetaxel market , including forecasts for subscribers. This continent databook contains high-level insights into Europe docetaxel market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe docetaxel market size, by country, 2018-2030 (US$M)
Europe Docetaxel Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
